Cellectis said it is exiting its CAR-T programs and pivoting toward “in vivo” gene editing, citing a shifting landscape and changes in how the company wants to deploy resources. The French biotech described the move as offloading lead programs and redirecting effort toward in vivo modalities. For the company, the decision is framed as strategic transformation after years in donor-derived cell therapy research. The pivot highlights how competitive economics and evolving clinical standards are forcing developers to re-evaluate whether CAR-T remains aligned with their near- and mid-term pipeline strategy.